Investment Rating - The report maintains a "Positive" investment rating for the investment banking and brokerage industry [7] Core Insights - The industry experienced a pullback this week, with the China Securities Regulatory Commission (CSRC) holding a meeting to discuss specific measures for implementing capital market policies. Broker valuations and institutional holdings are at low levels, while trading volumes remain high. Investment banking and overseas business have shown month-on-month improvements, and the mid-year reports are expected to continue the high prosperity trend, indicating ongoing opportunities in the sector [2][4] - In the insurance sector, current valuations reflect a pessimistic market outlook on long-term investments. However, considering the medium to long-term interest rate spreads, current valuations are still deemed safe. The report favors companies with stable earnings and dividends, recommending Jiangsu Jinzu, China Ping An, and China Pacific Insurance. Additionally, it suggests companies like New China Life, China Life, Hong Kong Exchanges and Clearing, CITIC Securities, Dongfang Wealth, Tonghuashun, and Jiufang Zhitu Holdings based on performance elasticity and valuation levels [2][4] Industry Performance - The non-bank financial index decreased by 0.7% this week, with an excess return of -2.3% relative to the CSI 300, ranking 30th out of 31 industries. Year-to-date, the non-bank financial index has increased by 0.3%, with an excess return of -0.9% compared to the CSI 300, also ranking 22nd out of 31 [5] - Market activity has cooled, with an average daily trading volume of 1,441.396 billion yuan, down 3.05% week-on-week, and an average turnover rate of 1.75%, down 8.10 basis points. However, the leverage capital scale has rebounded, with a margin balance of 1.86 trillion yuan, up 1.12% [5] Key Industry News & Company Announcements - The Shenzhen Stock Exchange released guidelines for the recognition standards of "light assets and high R&D investment" for companies listed on the Growth Enterprise Market [6] - The CSRC held a meeting to discuss specific measures for implementing capital market policies, emphasizing the need for a stable market environment and risk prevention [6][62] - Dongxing Securities has received approval from the CSRC for a change in its controlling shareholder to Huijin Company [6]

Core Viewpoint - The insurance sector in A-shares has shown significant growth since April, with companies like New China Life Insurance nearing historical highs and China People's Insurance Group reaching a six-year peak, indicating a bullish market trend for insurance stocks [1] Group 1: Market Dynamics - The recent rise in insurance stocks is attributed to both funding and fundamental factors. Institutional investors have increased their allocation to insurance stocks due to their potential to outperform indices and higher elasticity in a low-interest-rate environment [2] - Insurance companies are expected to enhance their equity allocation, positioning themselves as a "second flag bearer" in the bull market due to the expansion of equity risk appetite among various institutions [2] Group 2: Fundamental Factors - The insurance sector is benefiting from macroeconomic improvements and a favorable capital market environment, with expectations of enhanced performance for insurance companies as the economy recovers [3] - The cost of liabilities for life insurance is expected to improve, with a projected decrease in the preset interest rate for insurance products, which could lower the rigid liability costs [3] - The growing emphasis on commercial health insurance is creating new growth opportunities, supported by national policies that promote a multi-tiered medical security system [3] Group 3: Future Outlook - Analysts emphasize the importance of asset-liability matching for insurance stocks, which is crucial for determining their "real value" in a low-interest-rate environment [4] - The ongoing policy guidance aimed at reducing liability costs and expense ratios is expected to enhance profit levels in the life insurance sector, with projections indicating a potential turning point in effective business value returns by 2025 [4]

Group 1 - The company, Xinhua Life Insurance Co., Ltd., has approved an investment in a private fund initiated by Guofeng Xinghua (Beijing) Private Fund Management Co., Ltd. [1] - The fund, named Guofeng Xinghua Honghu Zhiyuan Phase III Private Securities Investment Fund No. 1, has a total scale of 22.5 billion RMB, with the company committing to invest 11.25 billion RMB [1] - The investment decision was made during the 34th meeting of the company's 8th Board of Directors [1] Group 2 - The fund's establishment is subject to regulatory procedures, including fund registration, which introduces a degree of uncertainty regarding the implementation timeline [2] - Other major terms of the fund contract have not undergone significant changes compared to the previously disclosed announcement [2]

新华人寿保险股份有限公司 关于对外投资的进展公告 新华人寿保险股份有限公司董事会及全体董事保证本公告内容不存 在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担法律责任。 一、 交易概述 新华人寿保险股份有限公司（以下简称"本公司"）第八届董事会第三十四 次会议审议通过了《关于申请投资试点基金三期1号的议案》，本公司拟出资认购 由国丰兴华（北京）私募基金管理有限公司（以下简称"国丰兴华"或"基金管 理人"）发起设立的私募基金（以下简称"基金"或"私募基金"）的份额。上述 事宜具体情况详见本公司于2025年6月13日刊载于上海证券交易所网站（http://w ww.sse.com.cn）的《新华保险关于对外投资的公告》（公告编号：2025-034号， 以下简称"相关公告"）。 A股证券代码：601336 A股证券简称：新华保险 编号：2025-040号 H股证券代码： 01336 H股证券简称：新华保险 二、 进展情况 2025 年 7 月 4 日，本公司与基金管理人国丰兴华及基金托管人广发银行股 份有限公司北京分行签署《国丰兴华鸿鹄志远三期私募证券投资基金 1 号基金合 同》（以 ...

Core Viewpoint - Insurance capital is increasingly active in the capital market, with a significant acceleration in shareholding actions, indicating a strong interest in dividend stocks, particularly in the banking sector and public utilities [1][4]. Group 1: Shareholding Actions - As of July 2, 2025, insurance companies have made 18 shareholding actions, surpassing the total of 20 for the entire year of 2024 and significantly exceeding the 2023 total [1][4]. - Li'an Life announced a shareholding action in Jiangnan Water, increasing its stake from 4.91% to 5.03% after purchasing 1.1 million shares [3]. - Major shareholders like Great Wall Life are also actively buying shares, indicating a trend of increased participation in the market [4]. Group 2: Investment Focus - The focus of insurance capital has shifted towards H-shares and banking stocks, which are favored due to their significant discounts compared to A-shares and high dividend yields above 5% [4][8]. - The stable profitability and low volatility of banking stocks, especially state-owned banks, align with the risk preferences of insurance capital [4][9]. - The regulatory environment has become more favorable, encouraging insurance funds to increase their equity investments, with a reported 34.9 trillion yuan in investment balance as of Q1 2025, a 16.7% year-on-year increase [8]. Group 3: Strategic Implications - Insurance companies are not only focusing on financial returns but also on industrial synergy, as seen in the case of Huaxia Life's investment in Hangzhou Bank to enhance insurance and banking collaboration [5]. - The trend of shareholding actions is expected to continue, with a potential diversification into sectors like public utilities, environmental protection, and transportation, which offer stable cash flows and are less affected by economic cycles [9][10]. - Future investments are likely to prioritize high-dividend, high-capital appreciation potential companies, aligning with the long-term, stable needs of the insurance industry [10].

对于大多数人身险公司来说，理赔金额中占比较大的依旧为医疗险理赔和重疾险理赔。例如，招商信诺人寿上半年各类型赔付金融占比中，医疗 险占比64.99%，重疾险占比22.74%。 当前，恶性肿瘤仍是健康"头号杀手"，且年轻化趋势明显。不过，就重疾险赔付而言，保额相对治疗平均花费仍有较大差距。中国人寿在理赔半 年报中提到，2025年上半年，重疾件均赔付金额约4万元，现有保障水平仍有不足。 盘古智库高级研究员江瀚对此表示，首先，消费者在保险配置过程中应注意选择覆盖范围广、保额充足的保险产品，确保能够应对重大疾病的治 疗和康复费用。其次，考虑到重疾险赔付金额与实际需求之间存在的较大缺口，建议消费者除了购买基础的重大疾病保险外，还可以考虑附加其 他类型的健康保险以补充保障。此外，为了尽可能降低重疾风险，个人应注重健康管理，定期体检，及时发现并处理潜在的健康问题。 理赔被称为保险行业服务的"最后一公里"，体验好坏直接决定行业口碑。7月2日，北京商报记者注意到，近期，中国人寿、新华保险、富德生命 人寿、百年人寿、招商信诺人寿、复星保德信人寿等多家保险机构陆续发布2025年上半年理赔报告，涉及理赔金额、理赔数量、获赔率、理赔支 ...

Core Viewpoint - The analysis of new business acquisition cost rates in the life insurance sector indicates that a higher acquisition cost does not necessarily correlate with lower profitability for new business, challenging conventional wisdom in the industry [1][6][24]. Group 1: New Business Acquisition Cost Rate - The formula for calculating the new business acquisition cost rate is defined as the cash flow from acquiring insurance contracts divided by the present value of future cash inflows from those contracts [1][11]. - In 2024, the aggregated new business acquisition cost rate for 12 life insurance companies was 8.4%, a decrease of 0.8 percentage points year-on-year [17]. - The new business profit margin for the same group of companies was 8.7%, reflecting a year-on-year decline of 0.4 percentage points [19]. Group 2: Performance of Individual Companies - Among the 12 companies, Ping An Life had the highest new business acquisition cost rate at 11.9%, followed by Taiping Life at 9.6% [19]. - The analysis revealed that loss-making contracts had a new business acquisition cost rate of 5.7%, while non-loss-making contracts had a rate of 8.7%, suggesting that higher quality, potentially profitable business requires greater investment in acquisition [19][22]. - Companies primarily using the bancassurance channel, such as Zhong Postal Life and Sunshine Life, experienced a 2.5 percentage point decrease in their new business acquisition cost rates due to the "reporting and operation integration" effect [21][22]. Group 3: Insights on Cost and Profitability Relationship - The relationship between new business acquisition cost rates and profit margins is complex; higher acquisition costs do not equate to lower profit margins, which contradicts common assumptions [6][24]. - The analysis indicates that companies with higher acquisition costs often achieve higher profit margins, likely due to their investment in acquiring higher quality business [7][26]. - The findings suggest that the main distribution channels for leading companies remain focused on individual agents, which influences their cost structures and profitability [4][26].

Core Viewpoint - The third batch of insurance fund long-term investment pilot programs is being approved, introducing new small and medium-sized insurance companies alongside larger firms, marking a significant shift in participation and investment models [1][2]. Group 1: Third Batch Pilot Program - The third batch of pilot institutions includes several small and medium-sized insurance companies, such as Zhonghui Life and bank-affiliated insurers like Nongyin Life and Jiaoyin Life, with asset sizes exceeding one billion [1]. - The Financial Regulatory Administration plans to approve an additional 60 billion yuan for the pilot program, increasing the total scale of long-term investment pilots to 222 billion yuan [3][4]. - The Honghu Fund Phase III, approved for 40 billion yuan, will focus on investing in well-governed, stable-operating, and dividend-paying large-cap blue-chip stocks [2][3]. Group 2: New Participation Models - The third batch introduces a new model where private fund managers manage third-party insurance funds, differing from previous batches where fund managers were from the same insurance system [2]. - Many small insurance companies lack their own asset management firms and prefer to invest in existing private funds established by other insurance asset management companies to benefit from the pilot program [2][3]. - This new model may enhance the efficiency and success rate of small insurance companies participating in the pilot, while also providing asset management firms with new business opportunities [3]. Group 3: Impact on the Insurance Industry - The long-term investment pilot aims to alleviate profit volatility for insurance companies and enhance equity investments, contributing to market stability and fostering a positive interaction between insurance funds and capital markets [4]. - The pilot program is seen as a means to address barriers to insurance capital entering the market, with accounting methods like equity method accounting and OCI helping to mitigate the impact of market fluctuations on insurance company profit statements [3].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年6月30日 狀態: 新提交 第 1 頁 共 10 頁 v 1.1.1 致：香港交易及結算所有限公司 公司名稱: 新華人壽保險股份有限公司 呈交日期: 2025年7月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01336 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,034,107,260 | RMB | | | 1 RMB | | 1,034,107,260 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 1,034,107,260 | RMB | | | 1 RMB | | ...

南方财经全媒体记者 孙诗卉 实习生 涂盛青 上海报道 近日，多款百万医疗险上新，21世纪经济报道记者发现，百万医疗险"卷"药品责任成为产品升级新趋 势。具体来看，多款产品对特药目录进行了扩容、放开了外购药责任，尤其在外购药责任方面做出了极 大的突破。 以往，不限清单的外购药责任仅出现在高端医疗险产品责任中，而普通的百万医疗几乎是没有产品可以 扩展外购药责任。 之所以出现这样的趋势，众安保险资深产品专家王顺对21世纪经济报道记者解释称，一方面原因是患者 的实际就医需求，在实际就医过程中患者可能遇到的用药限制，在癌症重症治疗领域中，患者也需要长 期自费购买免疫或靶向药，通过设计外购药责任，可以大幅降低经济负担，解决用户实际痛点。 另一方面，医疗险的基础责任趋同，而外购药的增设也同时提升了产品的竞争力，针对清单范围内的特 药、高昂价格药品提供特药直付和用药追踪，将 "报销环节" 延伸至 "治疗全流程"，降低患者垫资压力 的同时，也通过审核规范用药减少理赔纠纷。 事实上，自按疾病诊断相关分组（DRG）和按病种分值付费（DIP）支付方式的多项改革措施在全国范 围内加速推进，许多价格较高的原研药、进口药，以及一些非医保目 ...